Annexon biosciences appoints bettina m. cockroft, m.d.

Brisbane, calif., jan. 20, 2022 (globe newswire) -- annexon, inc. (“annexon”) (nasdaq: annx), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders, today announced the appointment of biotech executive bettina m. cockroft, m.d., senior vice president and chief medical officer of sangamo therapeutics, inc., to the company's board of directors.
ANNX Ratings Summary
ANNX Quant Ranking